J. W. Coons Advisors LLC Lowers Stock Position in Pfizer Inc. (NYSE:PFE)

J. W. Coons Advisors LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 11.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 39,021 shares of the biopharmaceutical company’s stock after selling 5,100 shares during the period. J. W. Coons Advisors LLC’s holdings in Pfizer were worth $1,123,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. VisionPoint Advisory Group LLC raised its holdings in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the period. GoalVest Advisory LLC lifted its position in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares in the last quarter. Tennessee Valley Asset Management Partners purchased a new stake in Pfizer during the fourth quarter worth approximately $36,000. DiNuzzo Private Wealth Inc. acquired a new stake in shares of Pfizer in the fourth quarter worth $37,000. Finally, Life Planning Partners Inc purchased a new position in shares of Pfizer in the 4th quarter valued at $39,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $28.59 on Friday. The firm has a market cap of $162.01 billion, a PE ratio of -476.42, a price-to-earnings-growth ratio of 1.16 and a beta of 0.70. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37. The firm’s 50-day simple moving average is $27.50 and its 200-day simple moving average is $27.88. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFEGet Free Report) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter last year, the business posted $1.23 EPS. Pfizer’s quarterly revenue was down 19.5% compared to the same quarter last year. Equities analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 5.88%. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PFE. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. Finally, Morgan Stanley boosted their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $35.86.

View Our Latest Stock Report on PFE

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.